CELL INTELLIGENCE · 肿瘤细胞治疗研究

辐照 CD19 嵌合抗原受体 YTS 细胞保留抗肿瘤活性并可作为自体 CAR-T 疗法的可规模化替代方案

Irradiated CD19 chimeric antigen receptor YTS cells retain antitumor activity and offer a scalable alternative to autologous CAR-T therapy.

超越传统嵌合抗原受体：拓展 CAR-T 细胞疗法中的可靶向抗原版图

Beyond Conventional Chimeric Antigen Receptors: Expanding the Targetable Antigen Landscape in Chimeric Antigen Receptor-T Cell Therapy.

CAR-T 细胞治疗前基于苯达莫司汀的淋巴细胞清除：一项系统综述

Bendamustine-based lymphodepletion prior to CAR T-cell therapy: a systematic review.

多发性骨髓瘤的治疗前沿：临床试验新兴格局分析

Therapeutic Horizon in Multiple Myeloma: Analysis of the Emerging Landscape of Clinical Trials.

多发性骨髓瘤临床试验的增加凸显了向生物治疗的转变，尤其是免疫治疗和 CAR-T 等基因治疗。

接受抗 BCMA CAR-T 细胞治疗的多发性骨髓瘤患者的病毒再激活

Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell Therapy.

CAR-T 细胞在血液系统恶性肿瘤中的进展、挑战与未来方向

CAR T-cells in hematologic malignancies: Advances, challenges, and future directions.

超越 CAR-T：CAR-NK/T 细胞在血液肿瘤中的兴起

Beyond CAR-T: The Rise of CAR-NK/T Cells for Haematological Cancer.

CAR-NK/T 细胞可能被证明是治疗血液系统恶性肿瘤的一种更安全、更灵活的细胞疗法。

多发性骨髓瘤 CAR 治疗的靶点

Targets for CAR Therapy in Multiple Myeloma.

挖掘基因编辑技术克服 T 细胞恶性肿瘤中 CAR-T 细胞治疗当前瓶颈的潜力

Harnessing the potential of gene-editing technology to overcome the current bottlenecks of CAR-T cell therapy in T-cell malignancies.

SOHO 前沿进展与待解问题｜老年弥漫大 B 细胞淋巴瘤：综合综述

SOHO State of the Art Updates and Next Questions | Diffuse Large B-Cell Lymphoma in Older Adults: A Comprehensive Review.